High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana

World Health Organization (WHO), 2014 Ghana National TB Control Programme, Guidelines for Management of Multidrug-Resistant Tuberculosis in Ghana, 2012, RNTCP; Ghana. Available: <http://www.tbghana.gov.gh/ntp-publications> (Accessed 10th March 2016). World Health Organization, 2015 Boehme, 2011, Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet, 377, 1495, 10.1016/S0140-6736(11)60438-8 Boehme, 2010, Rapid molecular detection of tuberculosis and rifampin resistance, N. Engl. J. Med., 363, 1005, 10.1056/NEJMoa0907847 Pantoja, 2013, Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis, Eur. Respir. J., 42, 708, 10.1183/09031936.00147912 World Health Organization, 2014 World Health Organization, 2014 Lebina, 2015, The use of decentralized GeneXpert by trained non-laboratory technicians in rural clinics in South Africa, Tuberculosis, 95, 625, 10.1016/j.tube.2015.05.006 van Kampen, 2015, Effect of introducing Xpert MTB/RIF to test and treat individuals at risk of multidrug-resistant tuberculosis in Kazakhstan: a prospective cohort study, PLoS One, 10, e0132514, 10.1371/journal.pone.0132514 Steingart, 2014, Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults, Cochrane Database Syst. Rev., 1, 3 Getahun, 2007, Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes, Lancet, 369, 2042, 10.1016/S0140-6736(07)60284-0 World Health Organization, 2014 Mukherjee, 2004, Programs and principles in treatment of multidrug-resistant tuberculosis, Lancet, 363, 474, 10.1016/S0140-6736(04)15496-2